Behçet Disease
4
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Peptide
1100%
+ 1 programs with unclassified modality
On Market (2)
Approved therapies currently available
U
APREMILASTApproved
apremilast
Unknown Companyoral2024
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AmgenApremilast
SoligenixDusquetide
Clinical Trials (2)
Total enrollment: 68 patients across 2 trials
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Start: Sep 2021Est. completion: Dec 203060 patients
Phase 3Recruiting
Dusquetide for the Treatment of Behcet's Disease
Start: Nov 2024Est. completion: Jun 20258 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 68 patients
Peptide is the dominant modality (100% of programs)
2 companies competing in this space